

NOSOCOMIAL *ENTEROBACTER* INFECTIONS: MECHANISMS OF RESISTANCE, CLINICAL IMPACT, AND INFECTION CONTROL STRATEGIES

*¹Dr. Nawal S. Faris, ²Dr. Omar M. Hadieh, ³Dr. Mohammad M. Hadieh

¹Department of Allied Medical Sciences, Middle East University.

^{2,3}Medicinal and Pharmaceutical Chemistry, Jordan University and Technology.

Article Info:

Received: 23 July 2026,

Revised: 13 August 2026,

Accepted: 03 September 2026

***Corresponding Author: Dr. Nawal S. Faris**

Department of Allied Medical Sciences, Middle East University.

DOI: <https://doi.org/10.5281/zenodo.22548166>



Citation:

*¹Dr. Nawal S. Faris, ²Dr. Omar M. Hadieh, ³Dr. Mohammad M. Hadieh. (2026). Nosocomial *Enterobacter* Infections: Mechanisms Of Resistance, Clinical Impact, And Infection Control Strategies. International Journal of Clinical and Pharmaceutical Innovations, 1(6), 187-197.

ABSTRACT

Enterobacter species, particularly *Enterobacter cloacae* complex and *Enterobacter aerogenes* (reclassified as *Klebsiella aerogenes*), represent significant opportunistic pathogens responsible for an increasing proportion of nosocomial infections worldwide. Their propensity to colonize immunocompromised individuals and patients in intensive care units (ICUs) presents a major clinical challenge. This review provides a comprehensive analysis of the core resistance mechanisms, clinical implications, and infection control strategies associated with nosocomial *Enterobacter* infections. Mechanistically, *Enterobacter species* possess a formidable array of intrinsic and acquired resistance determinants. Central to their drug-resistant phenotype is the inducible, chromosomally encoded *AmpC* β -lactamase. Exposure to β -lactam antibiotics frequently selects for derepressed mutants that constitutively overproduce *AmpC*, conferring resistance to third-generation cephalosporins and monobactams. Furthermore, the rapid dissemination of plasmid-mediated resistance genes—including extended-spectrum β -lactamases (ESBLs) and carbapenemases (such as KPC, NDM, VIM, and OXA-48-like variants)—has severely compromised carbapenem utility. Coupled with efflux pump overexpression, porin mutations, and aminoglycoside-modifying enzymes, multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains have emerged rapidly. Clinically, *Enterobacter* infections manifest primarily as ventilator-associated pneumonia, central line-associated bloodstream infections, catheter-associated urinary tract infections, and surgical site infections. These infections are correlated with prolonged hospital stays, heightened healthcare costs, and elevated morbidity and mortality, particularly when inappropriate empirical antimicrobial therapy is administered. The narrow range of remaining effective therapeutic options—often restricted to newer β -lactam/ β -lactamase inhibitor combinations, cefiderocol, polymyxins, or tigecycline—underscores the critical nature of these pathogens.

KEYWORDS: Enterobacter, Nosocomial infections, AmpC β -lactamase, Carbapenem resistance, Antibiotic stewardship, Infection control.

1. INTRODUCTION

Nosocomial infections—commonly referred to as hospital-acquired infections (HAIs) remain a major threat to patient safety, clinical outcomes, and healthcare sustainability globally. Among the diverse spectrum of Gram-negative pathogens driving these infections, members of the genus *Enterobacter* have emerged as particularly troublesome clinical agents. As prominent components of the ESKAPE group (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter species*), these organisms are characterized by their ability to escape the bactericidal action of conventional antimicrobial agents, thereby presenting profound therapeutic challenges in modern medical settings.^[1]

Historically regarded as low-virulence opportunistic pathogens inhabiting the human gastrointestinal tract and various environmental niches, *Enterobacter species* have undergone a significant clinical transformation over the past few decades. In modern hospital environments, particularly within intensive care units (ICUs), surgical wards, and oncology units, these organisms readily colonize vulnerable patients. Individuals compromised by underlying comorbidities, prolonged critical illness, invasive medical devices (such as central venous catheters, urinary catheters, and mechanical ventilators), or extensive exposure to broad-spectrum antibiotics are at exceptional risk. Clinical manifestations of nosocomial *Enterobacter* infections are varied and severe, ranging from ventilator-associated pneumonia (VAP) and catheter-related bloodstream infections (CRBSIs) to complex intra-abdominal infections, urinary tract infections (UTIs), and surgical site infections (SSIs). What sets *Enterobacter* apart from many other nosocomial pathogens is its complex, dynamic, and multi-layered resistance machinery.^[2]

The hallmark of resistance in this genus is the chromosomally encoded, inducible Class C β -lactamase (*AmpC*). Under basal conditions, *AmpC* expression is tightly regulated; however, exposure to certain β -lactam agents or the selection of stable derepressed mutants leads to hyperproduction of the enzyme. This renders third generation cephalosporins—traditionally the backbone of therapy against Gram-negative bacilli—ineffective. Compounding this intrinsic mechanism is the continuous acquisition of mobile genetic elements carrying plasmid-mediated extended-spectrum β -lactamases (ESBLs) and carbapenemases (such as KPC, NDM, and OXA-48-like enzymes).^[3,9] Consequently, clinicians are increasingly confronted with multidrug-resistant (MDR) and extensively drug-resistant (XDR) *Enterobacter* isolates that display resistance to carbapenems, historically considered the drugs of last resort. The clinical impact of these resistant strains is substantial. Inappropriate initial empirical antimicrobial therapy a common occurrence when dealing with derepressed *AmpC* producers or carbapenemase

producers—is directly correlated with increased patient mortality, prolonged length of stay, and escalated healthcare costs. Furthermore, the pipeline for novel, highly effective antibiotics capable of overcoming all mechanisms of resistance simultaneously remains limited, forcing clinicians to rely on newer β -lactam/ β -lactamase inhibitor combinations or older, potentially toxic agents such as polymyxins and aminoglycosides. Addressing the threat posed by nosocomial *Enterobacter* infections requires a comprehensive approach that bridges molecular biology, clinical pharmacology, and hospital epidemiology. This review provides an in-depth examination of the mechanisms driving resistance in *Enterobacter species*, evaluates their clinical burden and therapeutic limitations, and outlines evidence-based infection control and antimicrobial stewardship strategies necessary to curb their transmission and preserve existing treatment modalities.^[4,6]

2. METHODOLOGY

To build this review, I gathered literature through targeted searches across PubMed, MEDLINE, and Google Scholar, focusing on studies published between 2000 and 2026. My search strategy used both individual keywords and combinations of key terms, including *Enterobacter cloacae* complex, *Klebsiella aerogenes*, *AmpC* β -lactamase derepression, carbapenemase-producing *Enterobacteriaceae*, nosocomial pneumonia, bloodstream infections, and antimicrobial stewardship. When evaluating articles for inclusion, I prioritized work based on its clinical relevance, methodological soundness, and value to updated epidemiological trends. I gave preference to prospective clinical trials, multicenter surveillance data, detailed molecular characterization studies, and established consensus guidelines from international bodies such as the CDC, WHO, IDSA, and ESCMID. To maintain a strong evidence base, I excluded single case reports, preprints, and non-peer-reviewed sources. After critically appraising the selected literature, I organized the findings into structured thematic sections covering clinical features, genetic resistance pathways, current treatment choices, and infection control measures.

3. Epidemiology and Clinical Manifestations

3.1. Global Epidemiology and Risk Factors

Over the past two decades, the clinical epidemiology of *Enterobacter* has undergone a dramatic shift. Once considered low-grade opportunists, members of the *Enterobacter cloacae* complex (ECC) and *Klebsiella aerogenes* are now consistently ranked among the top ten most frequent causes of intensive care unit (ICU)–acquired infections worldwide.^[7,17]




Figure 1: pathogen colonization & transmission of *Enterobacter*.

While *Enterobacter* can occasionally cause community-onset infections in elderly or multimorbid individuals, it remains predominantly a pathogen of the high-dependency hospital setting. Transmission follows two main pathways:

- Endogenous Colonization: Patients undergoing prolonged broad-spectrum antibiotic therapy experience suppression of their normal gastrointestinal microflora, allowing low-level intestinal *Enterobacter* populations to overgrow, translocate, or contaminate the skin.
- Exogenous Cross-Transmission: The organism transfers via transiently contaminated healthcare worker hands or colonizes abiotic surfaces, medical equipment, and water sources. [Figure,1]
- Critical illness requiring prolonged ICU stays (>7 days).
- Presence of indwelling invasive devices (e.g., central venous catheters, urinary catheters, endotracheal tubes).
- Recent, repeated courses of broad-spectrum antimicrobials—particularly third-generation cephalosporins, fluoroquinolones, and carbapenems.
- Immunosuppression, neutropenia, extensive burn injuries, or major [Table, 1] gastrointestinal surgery.^[8,19]

High-Risk Patient Populations

The acquisition of *Enterobacter* infections is rarely random; it concentrates heavily in patients with specific underlying vulnerabilities:

Table 1: Comparative Classification and Epidemiological Features of Clinical *Enterobacter* Species.

Species / Complex	Historical Name / Reclassification	Primary Clinical Isolates	Natural Reservoirs	Key Clinical Features & Associated HAIs
<i>Enterobacter cloacae</i> Complex (ECC)	N/A (Includes multiple genomic clusters/species)	<i>E. cloacae</i> , <i>E. hormaechei</i> , <i>E. asburiae</i> , <i>E. ludwigii</i>	Gastrointestinal tract, soil, aquatic environments	Leading cause of ICU-acquired bacteremia, CLABSIs, VAP, and intra-abdominal infections; high prevalence of mobile resistance elements.
<i>Klebsiella aerogenes</i>	<i>Enterobacter aerogenes</i> (Reclassified in 2017)	<i>K. aerogenes</i>	Gastrointestinal tract, hospital equipment	Frequent culprit in post-surgical wound infections, VAP, and CAUTIs; exhibits high rate of inducible AmpC and rapid porin loss.
<i>Enterobacter kobei</i>	Member of ECC	<i>E. kobei</i>	Clinical specimens, environmental water	Emerging opportunistic pathogen in neonatal ICUs and immunocompromised patients; often misidentified by standard biochemical kits.
<i>Enterobacter bugandensis</i>	Newly identified high-risk clone	risk clone <i>E. bugandensis</i>	Hospital environment, clinical isolates	Hypervirulent and multidrug-resistant; associated with severe neonatal sepsis and increased persistence on inert surfaces

3.2. Clinical Manifestations

Because *Enterobacter* lacks strict tissue tropism, it can infect almost any anatomical site where host defenses are compromised or anatomical barriers are breached.

1. Ventilator-Associated Pneumonia (VAP) and Lower Respiratory Infections Hospital-acquired pneumonia (HAP) and VAP represent the most frequent and life-threatening presentations of *Enterobacter*. Intubated patients quickly accumulate a proteinaceous biofilm along the inner lumen of the endotracheal tube. Aspiration of contaminated upper airway secretions or micro-aspiration of gastrointestinal flora introduces the organism directly into the lower respiratory tract. Patients typically present with purulent tracheal secretions, worsening oxygenation (PaO₂/FiO₂ ratio drop), new pulmonary infiltrates on chest imaging, and systemic signs of sepsis.

2. Bloodstream Infections (BSIs) and Sepsis *Enterobacter* bacteremia carries crude mortality rates ranging from 20% to 40%, depending on host immunity and the timeliness of effective antibiotic therapy. BSIs are generally categorized into two types: Secondary Bacteremia: Originating from an identified primary focus, such as a severe intra-abdominal infection, complicated pyelonephritis, or VAP. Primary / Catheter-Related BSIs (CRBSIs): Arising from central venous

catheters, where the organism forms a dense, protected biofilm on the internal or external catheter surface.

3. Catheter-Associated Urinary Tract Infections (CAUTIs) While less common than *Escherichia coli* or *Klebsiella pneumoniae*, *Enterobacter* is a frequent cause of CAUTIs in patients with long-term urinary catheterization or structural neurogenic bladder dysfunction. Clinical features range from asymptomatic bacteriuria and mild cystitis to ascending pyelonephritis, renal abscess formation, and secondary urosepsis.

4. Intra-Abdominal and Surgical Site Infections (SSIs) Following major abdominal surgery, liver transplantation, or intestinal perforation, *Enterobacter* frequently contributes to polymicrobial intra-abdominal sepsis, deep organ-space abscesses, and biliary tract infections. Its ability to survive in bile salts and co-exist alongside anaerobic flora makes eradication challenging without adequate surgical source control. [Table, 2]

5. Skin, Soft Tissue, and Device-Related Infections In burn units and trauma centers, *Enterobacter* readily colonizes open, exuding wound beds, surgical incisions, and chronic decubitus ulcers. While superficial colonization is common, invasive tissue necrosis and osteomyelitis can develop when host perfusion or local tissue integrity is severely compromised.^[8,12]

Table 2: Clinical Entity, Primary risk factors, and Common Clinical Features of *Enterobacter*.

Clinical Entity	Primary Risk Factors / Drivers	Common Clinical Features
Ventilator-Associated Pneumonia (VAP)	Prolonged intubation, micro-aspiration of upper airway colonizers	Purulent sputum, fever, new infiltrates on chest radiography
Central Line-Associated Bloodstream Infections (CLABSI)	Indwelling vascular access, compromised line hygiene	High fever, septic shock, metastatic foci in severe cases
Catheter-Associated Urinary Tract Infections (CAUTI)	Long-term urinary catheterization, structural urinary tract abnormalities	Pyuria, flank pain, secondary bacteremia
Surgical Site & Intra-abdominal Infections	Post-operative wound contamination, bowel perforation	Purulent drainage, localized tenderness,

4. Molecular Mechanisms of Antimicrobial Resistance

The clinical management of *Enterobacter* species is profoundly complicated by a dual-layered armory of resistance mechanisms. The primary barrier stems from a chromosomally encoded, inducible β -lactamase regulatory network. Compounding this intrinsic resistance is the rapid horizontal acquisition of plasmid-borne resistance determinants that encode extended-spectrum enzymes, carbapenemases, and efflux pathways.^[11]

4.1. The Intrinsic Chromosomal *AmpC* Regulatory Network

The hallmark genetic characteristic of the *Enterobacter cloacae* complex and *Klebsiella aerogenes* is the chromosomal *ampC* structural gene and its tightly coordinated regulatory system, which includes the

regulatory gene *ampR*, the transmembrane permease *ampG*, and the cytosolic N-acetylmuramyl-L-alanine amidase *ampD*.^[13]

Normal Basal Expression (Repression)

Under uninduced baseline conditions, the cell wall undergoes routine recycling. Peptidoglycan degradation fragments—specifically UDP-N-acetylmuramic acid (UDP-MurNAc)-pentapeptides—accumulate in the cytoplasm and bind to the LysR-type transcriptional regulator *AmpR*. In this state, *AmpR* functions as a repressor, binding to the operator region between *ampR* and *ampC* to maintain low-level, basal transcription of the *ampC* structural gene.^[14]

Inducible Pathway Activation

When *Enterobacter* is exposed to inducing β -lactam molecules (e.g., aminopenicillins, cefoxitin, or clavulanic acid), severe cell wall degradation occurs:

1. Peptidoglycan Degradation: β -lactam activity triggers an influx of cell wall cleavage products, primarily 1,6-anhydro-N-acetylmuramyl-peptides (anhMurNAC-peptides), in the periplasm.
2. Transmembrane Import: The membrane permease AmpG transports these anhMurNAC-peptides from the periplasm into the cytoplasm.
3. AmpD Saturation: Under low-level stress, the cytosolic amidase AmpD cleaves these peptides to recycle them into UDP-MurNAC-pentapeptides. However, during intense cell wall stress, the concentration of anhMurNAC-peptides overwhelms AmpD activity.
4. Conformational Shift: The excess anhMurNAC-peptides displace UDP-MurNAC-pentapeptide from AmpR. This ligand exchange induces a conformational shift in AmpR, transforming it from a transcriptional repressor into a potent activator.
5. AmpC Overproduction: Active AmpR dramatically upregulates the transcription of the *ampC* gene, leading to high-level synthesis of the Class C AmpC β -lactamase enzyme.^[15]

Derepression and On-Treatment Selection

While induction is a reversible physiological response that subsides once the inducing drug is cleared, exposure to non-inducing or weak-inducing β -lactams (such as ceftriaxone, cefotaxime, or ceftazidime) presents a dangerous selective pressure. Within any high-inoculum population of *Enterobacter*, spontaneous loss-of-function mutations occur in regulatory genes—most commonly *ampD* or, less frequently, structural mutations in *ampR*.^[16]

These "derepressed mutants" continuously transcribe *ampC* at maximum capacity without requiring an inducer. During clinical treatment with third-generation cephalosporins, wild-type susceptible cells are eradicated while pre-existing derepressed mutants are selected out, leading to treatment failure. [Figure, 2]

4.2. Plasmid-Mediated Resistance Determinants

Beyond their intrinsic chromosomal machinery, *Enterobacter* species readily serve as both recipients and reservoirs for mobile genetic elements via conjugative plasmids, transposons, and integrons.^[18]




Figure 2: Global Emergence and Clonal Dissemination of High-Risk Enterobacter Lineages.

Extended-Spectrum β -Lactamases (ESBLs)

Plasmid-acquired ESBL genes—predominantly belonging to the blaCTX-M family (such as CTX-M-15), as well as blaTEM and blaSHV variants—hydrolyze penicillins, broad-spectrum cephalosporins, and monobactams. Unlike AmpC enzymes, classical ESBLs are inhibited by clavulanic acid and tazobactam; however, co-expression of plasmid-mediated ESBLs alongside chromosomal *AmpC* derepression creates a complex phenotype that confers resistance across nearly all non-carbapenem β -lactams.^[20]

Carbapenemases

The global dissemination of carbapenem-resistant *Enterobacter* (CRE) is primarily driven by horizontal gene transfer across three molecular classes:

- Ambler Class A (Serine Carbapenemases): The plasmid-encoded *Klebsiella pneumoniae* carbapenemase (blaKPC) efficiently hydrolyzes all β -lactams, including carbapenems. These genes are typically carried on IncF-type conjugative plasmids associated with transposon Tn4401.
- Ambler Class B (Metallo- β -Lactamases): Enzymes such as New Delhi metallo- β -lactamase (blaNDM), Verona integron-encoded metallo- β -lactamase (blaVIM), and IMP variants require zinc ions for catalytic activity. They hydrolyze carbapenems and cephalosporins but spare aztreonam. However, isolates co-carrying NDM with ESBL or AmpC enzymes exhibit broad-spectrum resistance to virtually all standard β -lactams. [Table 3]

- Ambler Class D (Oxacillinases): blaOXA-48-like variants confer weak hydrolysis of carbapenems and spare expanded-spectrum cephalosporins, but often cause high-level carbapenem resistance when combined with permeability defects.^[21]

4.3. Auxiliary Mechanisms: Porins and Efflux Systems

In addition to enzymatic inactivation, physical barrier alterations synergize with β -lactamase production to elevate minimum inhibitory concentrations (MICs):

- Outer Membrane Porin Loss: Downregulation or truncation of major outer membrane porins—specifically OmpF and OmpC—restricts entry of β -

lactams and carbapenems into the periplasmic space. Porin loss combined with baseline AmpC production can convert a low-level resistant isolate into a fully carbapenem-resistant phenotype.

- Efflux Pump Overexpression: Upregulation of resistance-nodulation-division (RND) family efflux pumps, particularly the AcrAB-TolC system, actively pumps out non- β -lactam antibiotics, including fluoroquinolones, tetracyclines, tigecycline, and chloramphenicol, driving multidrug resistance across multiple drug classes.^[22]

Table 3: Key Genetic Mechanisms of Antimicrobial Resistance in Enterobacter.

Resistance Phenotype	Primary Resistance Genes / Mechanisms	Affected Antimicrobial Classes	Clinical Management Implications
Inducible AmpC β-Lactamase	Chromosomal ampC gene regulated by ampR, ampG, and ampD	Penicillins, aminopenicillins, 1st–3rd gen cephalosporins	High risk of treatment failure with ceftriaxone/cefotaxime due to selection of derepressed mutants during therapy.
Extended-Spectrum β-Lactamases (ESBLs)	Plasmid-mediated blaCTX-M, blaSHV, blaTEM	All cephalosporins, aztreonam	Neutralized by classic inhibitors (clavulanate, tazobactam); carbapenems remain first-line.
Carbapenem Hydrolysis (CPE)	blaKPC (Class A), blaNDM, blaVIM (Class B), blaOXA-48 (Class D)	All β -lactams including carbapenems	Requires advanced combination agents (e.g., ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol).
Outer Membrane	Mutations downregulating or truncating ompF / ompC expression	Carbapenems, fluoroquinolones	Acts synergistically with AmpC overproduction to elevate carbapenem MICs into resistant ranges.
Efflux Pump Overexpression	Upregulation of AcrAB-TolC efflux systems	Fluoroquinolones, tetracyclines, tigecycline, chloramphenicol	Confers multidrug resistance phenotype; limits non- β -lactam treatment alternatives.

Figure 2: Molecular Pathways of AmpC Induction and Co-Acquired β -Lactamase Resistance.

5. Clinical Management and Treatment

Managing Enterobacter infections in the clinical setting is often an exercise in risk management. Because these

organisms can rapidly adapt under drug pressure, picking the right antibiotic isn't just a matter of reading a microbiology susceptibility report—it requires anticipating how the bacteria will behave 48 to 72 hours into treatment.^[16]




Figure 3: Clinical a Susceptibility profile of Enterobacter bacteria.

The Third-Generation Cephalosporin Trap

The most critical rule in managing serious *Enterobacter* infections is avoiding third-generation cephalosporins (such as ceftriaxone, cefotaxime, or ceftazidime), even when the initial laboratory report labels the isolate as "susceptible."

"In high-bacterial-load infections—like ventilator-associated pneumonia or deep abdominal abscesses—spontaneous ampD derepression mutations exist within the bacterial population at a baseline frequency of roughly 1 in 105 to 107 cells. Exposing the culture to ceftriaxone quickly kills off the susceptible majority, but leaves behind the derepressed mutants. These mutants then proliferate unchecked, leading to clinical treatment failure mid-course.[Figure, 3]

Navigating Cefepime: The MIC Threshold

Cefepime remains our workhorse for wild-type or low-level AmpC-producing strains. Because cefepime is a weak inducer and resists hydrolysis by the AmpC enzyme, it passes through the bacterial periplasm relatively unscathed.

However, dosing and MIC thresholds are paramount:

- MIC ≤ 2 $\mu\text{g/mL}$: Cefepime is highly effective. To maximize efficacy, it should be administered at high doses (2 g IV every 8 hours) via extended infusions over 3 to 4 hours to keep drug levels above the MIC for as long as possible.
- MIC 4–8 $\mu\text{g/mL}$: Cefepime becomes unreliable due to inoculum effects and potential low-level enzyme activity. In these cases, clinicians should step up to a carbapenem.

The Role of Carbapenems For patients with severe sepsis, high-inoculum infections, or isolates exhibiting cefepime MICs above 2 $\mu\text{g/mL}$, carbapenems (meropenem or imipenem) are the definitive treatment of choice. They are non-inducers, stable against AmpC hydrolysis, and maintain high cure rates in ESBL-co-producing strains.

Ertapenem offers a convenient once-daily outpatient option for stable patients transitioning home, but it should be avoided in unstable ICU patients or when polymicrobial coverage for *Pseudomonas* is needed.^[8]

Tackling Carbapenem-Resistant *Enterobacter* (CRE)

When carbapenem resistance emerges, treatment decisions depend heavily on the underlying enzyme type:

- KPC Producers (Class A): Newer β -lactamase inhibitor combinations—specifically ceftazidime-avibactam and meropenem-vaborbactam—have largely replaced older, toxic regimens like colistin. Avibactam and vaborbactam effectively protect the partner β -lactam from KPC cleavage.
- Metallo- β -Lactamase Producers (Class B, e.g., NDM): Because metallo-enzymes break down most new inhibitors, a clever combination therapy is required: ceftazidime-avibactam plus aztreonam. Aztreonam natively escapes metallo- β -lactamase cleavage, while avibactam neutralizes any co-carried AmpC or ESBL enzymes that would otherwise degrade aztreonam. Cefiderocol, a novel siderophore cephalosporin, also serves as a strong monotherapy alternative in this setting.[Table 4]
- OXA-48 Producers (Class D): Ceftazidime-avibactam is preferred, as vaborbactam and relebactam do not reliably inhibit OXA-48 enzymes.^[14]

Non- β -Lactam Alternatives

For non-critically ill patients with lower urinary tract infections, non- β -lactam agents such as ciprofloxacin, levofloxacin, or trimethoprim-sulfamethoxazole (TMP-SMX) remain excellent step-down choices if susceptibility is documented. Older salvage agents like colistin, tigecycline, or high-dose amikacin are generally reserved as last-line options due to concerns over nephrotoxicity and poor tissue penetration in bloodstream infections.^[20]

Table 4: Evidence-Based Treatment Recommendations Based on Resistance Profile.

Phenotype / Scenario	Preferred Antimicrobial Regimen	Alternative / Second-Line Regimen	Agents to Avoid
Wild-type / Susceptible (Low AmpC Induction Risk)	Cefepime (2 g IV q8h)	Fluoroquinolones (ciprofloxacin/levofloxacin) or TMP-SMX (if susceptible)	3rd-generation cephalosporins (high induction risk)
High-Level AmpC Derepression (Cefepime MIC ≤ 2 $\mu\text{g/mL}$)	Cefepime (2 g IV q8h via extended infusion)	Meropenem (1–2 g IV q8h) or Imipenem-cilastatin	Ceftriaxone, cefotaxime, ceftazidime, piperacillin-tazobactam
ESBL-Producing / High AmpC (Cefepime MIC > 2 $\mu\text{g/mL}$)	Meropenem or Imipenem-cilastatin	Ertapenem (for non-critically ill without shock)	All cephalosporins, piperacillin-tazobactam
Carbapenem-Resistant (KPC-producing)	Ceftazidime-avibactam or Meropenem-vaborbactam	Cefiderocol or Colistin + Tigecycline	All standard β -lactams and carbapenems
Carbapenem-Resistant (NDM / Metallo-β-lactamase)	Ceftazidime-avibactam + Aztreonam OR Cefiderocol	Colistin-based	Novel single-agent β -lactamase inhibitor combinations

6. Infection Prevention and Control [Figure, 4]

Controlling the spread of *Enterobacter* in hospital environments is notoriously tricky. Unlike fragile pathogens that quickly die off outside the host, *Enterobacter species* are tough, environmental survivors. They persist on dry plastics, thrive in moist sinks, and

readily colonize inanimate equipment across intensive care units. Preventing cross-transmission requires a coordinated approach that targets environmental reservoirs, hand hygiene, and antimicrobial prescribing habits.^[19]




Figure 4: break the transmission chain of *Enterobacter* bacteria.

Hand Hygiene and Contact Precautions

The primary vector for *Enterobacter* cross-contamination remains the transiently contaminated hands of healthcare personnel. Standard alcohol-based hand rubs are generally effective against these Gram-negative bacilli, but compliance must be absolute—particularly before manipulating vascular lines, urinary catheters, or airway tubing.

For patients colonized or infected with multidrug-resistant (MDR) or carbapenem-resistant *Enterobacter* (CRE):

- Single-room isolation or dedicated cohorting is strongly advised to prevent ward-level outbreaks.
- Contact Precautions (gowns and gloves) should be strictly enforced upon entering the room.
- Dedicated equipment (e.g., stethoscopes, blood pressure cuffs, blood glucose meters) should remain in the patient's room until discharge.^[17, 19]

Environmental Decontamination and Fomites

Enterobacter species excel at forming resilient biofilms on abiotic surfaces. In critical care units, high-touch items—such as ventilator control panels, infusion pumps, bedside monitors, and IV poles—frequently act as secondary reservoirs.

Effective decontamination protocols must incorporate:

- Routine Disinfection: Using hospital-grade, EPA-registered disinfectants with proven activity against Gram-negative bio-burden.
- Focus on Moisture Centers: Sinks, drainage traps, and respiratory therapy equipment must be monitored closely, as stagnant water encourages biofilm formation and aerosolization.
- Terminal Cleaning Audits: Verifying cleaning thoroughness following patient discharge using fluorescent markers or adenosine triphosphate (ATP) bioluminescence assay swabs.^[22]

Antimicrobial Stewardship as an Infection Control Tool

You cannot separate infection control from antibiotic stewardship when dealing with *Enterobacter*. Heavy reliance on third-generation cephalosporins (ceftriaxone, cefotaxime) creates immense selective pressure in the ward, wiping out susceptible microflora and driving the selection and expansion of AmpC-derepressed or ESBL-producing strains.

Stewardship programs should focus on:

1. Cephalosporin Restriction: Restricting unnecessary third-generation cephalosporin use in ICUs directly correlates with lower rates of AmpC derepression.
2. De-escalation Protocols: Re-evaluating empirical broad-spectrum coverage as soon as culture and sensitivity results become available (ideally within 48 to 72 hours).
3. 3-Short-Course Therapy: Transitioning patients to the shortest effective clinical course for conditions like uncomplicated CAUTI or VAP to minimize drug-induced colonization resistance loss.

Care Bundle Adherence

Invasive medical devices provide direct entry portals for opportunistic *Enterobacter* colonization. Consistently enforcing evidence-based clinical care bundles remains one of our most effective preventative shields:

- VAP Bundles: Maintaining head-of-bed elevation (30°–45°), daily sedation interruptions, and routine subglottic secretion drainage. [Table 5]
- CLABSI & CAUTI Bundles: Utilizing strict aseptic techniques during insertion, maintaining closed drainage systems, and conducting daily multidisciplinary reviews to prompt early removal of unnecessary central lines and urinary catheters.^[12]

Table 5: Key Performance Indicators for Nosocomial *Enterobacter* Infection Control.

Intervention Domain	Target Measure / Bundle Element	Implementation Strategy	Expected Clinical Outcome
Diagnostic Stewardship	Rapid detection of AmpC and carbapenemase genes (PCR / MALDI-TOF)	Integration of molecular resistance panels directly from positive blood cultures	Reduces time to optimal targeted therapy; prevents inappropriate 3rd-gen cephalosporin use.
Antimicrobial Stewardship	Restriction and audit of 3rd-generation cephalosporins in ICUs	Prospective audit and feedback with mandatory infectious disease pre-authorization	Decreases selective pressure that drives ampC gene derepression and ESBL dissemination.
Device Bundle Compliance	Daily assessment of line necessity (CLABSI/CAUTI bundles)	Nurse-driven protocol for prompt catheter removal when criteria are no longer met	Reduces primary colonization sites for biofilm-forming <i>Enterobacter</i> strains.
Environmental Hygiene	Sporicidal/disinfectant cleaning of high-touch patient equipment	Terminal cleaning verification using fluorescent markers or ATP bioluminescence	Decreases horizontal transmission via contaminated mechanical ventilators and monitors.

7. Conclusion and Future Perspectives

7.1. Concluding Remarks

Enterobacter species specifically members of the *Enterobacter cloacae* complex and *Klebsiella aerogenes* have firmly established themselves among the most formidable opportunistic pathogens in contemporary hospital environments. Once regarded primarily as low-virulence commensals, their ability to exploit host vulnerabilities in intensive care units and high-dependency wards has transformed them into major drivers of healthcare-associated morbidity, mortality, and prolonged hospital stays.

The central clinical challenge presented by *Enterobacter* lies in its extraordinary genetic agility. Its intrinsic, chromosomally encoded *ampC* regulatory network creates a well-recognized therapeutic trap, where exposure to third-generation cephalosporins frequently drives on-treatment derepression and clinical failure. This intrinsic defense is now increasingly compounded by the horizontal acquisition of mobile genetic elements encoding extended-spectrum β -lactamases (ESBLs) and diverse carbapenemases (KPC, NDM, OXA-48), alongside porin loss and efflux pump activation.

Navigating these overlapping resistance traits requires a fundamental shift away from empirical decision-making toward mechanism-informed therapy. Managing these infections successfully depends on key clinical practices:

- Avoiding third generation cephalosporins for deep-seated or high-inoculum infections despite baseline in vitro susceptibility.
- Optimizing the administration of fourth generation cephalosporins (cefepime) via high-dose, extended-infusion regimens when MICs are ≤ 2 $\mu\text{g/mL}$.
- Rationally deploying carbapenems or novel β -lactamase inhibitor combinations (ceftazidime-avibactam, meropenem-vaborbactam) and siderophore cephalosporins (cefiderocol) for resistant phenotypes.

Ultimately, antimicrobial therapy alone cannot solve the *Enterobacter* problem. Curbing its clinical impact demands equal emphasis on ward-level infection prevention and control, rigorous device-bundle adherence, environmental hygiene targeting high-touch surfaces and moisture reservoirs, and strict antibiotic stewardship to reduce selective pressure.

7.2. Future Perspectives and Research Priorities

To stay ahead of the evolving resistance landscape of *Enterobacter*, future clinical and translational research must focus on several key frontiers:

- **Rapid Point-of-Care Molecular Diagnostics:** Developing and integrating rapid diagnostic platforms (such as direct-from-blood PCR panels, multiplex digital PCR, and rapid MALDI-TOF assays) that can detect both resistance genes (*blaKPC*, *blaNDM*, *blaOXA-48*) and specific regulatory mutations (such as *ampD* inactivation) within hours of culture positivity.
- **Novel Anti-Virulence Strategies:** Shifting focus from traditional bactericidal agents toward non-antibiotic therapeutics that target bacterial virulence without exerting lethal selective pressure. Priority areas include quorum sensing inhibitors, small-molecule disruptors of biofilm architecture, and agents targeting bacterial outer-membrane integrity.
- **Phage Therapy and Novel Modalities:** Evaluating engineered bacteriophage cocktails and phage-derived lytic enzymes (endolysins) as targeted, adjuvant therapies for clearing recalcitrant biofilm-associated infections on indwelling medical devices.
- **Genomic Surveillance and Phylogenomics:** Expanding global whole-genome sequencing (WGS) initiatives to monitor the emergence, clonal expansion, and plasmid-transfer dynamics of high-risk international *Enterobacter* lineages across animal, environmental, and clinical interfaces.
- **Clinical Trial Data for Emerging Regimens:** Conducting prospective, randomized controlled

trials to establish optimal dosing, duration, and potential synergistic combinations for novel β -lactamase inhibitor formulations and non-traditional salvage agents against metallo- β -lactamase-producing isolates

8- REFERENCES

1. Castanheira, M., Simmer, P. J., & Bradford, P. A. (2021). Extended-spectrum β -lactamases, AmpC, and carbapenemases among *Enterobacterales*: Review of definitions, epidemiology, and detection. *Journal of Clinical Microbiology*, 59(7): e02700-20. <https://doi.org/10.1128/JCM.02700-20>, Cited by: 312
2. Davin-Regli, A., Lavigne, J. P., & Pagès, J. M. (2019). *Enterobacter spp.*: Update on taxonomy, clinical aspects, and susceptibility to antibiotics. *Clinical Microbiology Reviews*, 32(4): e00002-19. <https://doi.org/10.1128/CMR.00002-19>, Cited by: 420
3. Harris, P. N. A., Wei, J. Y., Shen, M. W., Tambyah, P. A., Paterson, D. L., & Ferguson, J. K. (2016). Carbapenems versus alternative β -lactams for the treatment of bloodstream infections caused by *Enterobacter*, *Citrobacter* or *Serratia* species: A systematic review and meta-analysis. *Journal of Antimicrobial Chemotherapy*, 71(2): 296–306. <https://doi.org/10.1093/jac/dkv346>, Cited by: 185
4. Jacoby, G. A. (2009). AmpC β -lactamases. *Clinical Microbiology Reviews*, 22(1): 161–182. <https://doi.org/10.1128/CMR.00036-08>, Cited by: 1850
5. Mezzatesta, M. L., Gona, F., & Stefani, S. (2012). *Enterobacter cloacae* complex: Clinical impact and emerging antibiotic resistance. *Future Microbiology*, 7(7): 887–902. <https://doi.org/10.2217/fmb.12.61>, Cited by: 803
6. Potter, R. F., Lainhart, W., Twentyman, J., Wallace, M. A., Wang, B., Burnham, C. A., & Dantas, G. (2018). Population genomics of *Enterobacter cloacae* complex isolates recovered from a single hospital system over a 10-year period. *mBio*, 9(5): e01479-18. <https://doi.org/10.1128/mBio.01479-18>, Cited by: 145
7. Sanders, C. C., & Sanders, W. E. Jr. (1986). Type I β -lactamases of gram-negative bacteria: Interactions with β -lactam antibiotics. *The Journal of Infectious Diseases*, 154(5): 792–800. <https://doi.org/10.1093/infdis/154.5.792>, Cited by: 620
8. Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2021). Infectious Diseases Society of America guidance on the treatment of AmpC β -lactamase-producing *Enterobacterales*, carbapenem-resistant *Acinetobacter baumannii*, and *Stenotrophomonas maltophilia* infections. *Clinical Infectious Diseases*, 74(12): 2089–2114. <https://doi.org/10.1093/cid/ciab1013>, Cited by: 647
9. Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2022). Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β -lactamase producing *Enterobacterales* (ESBL-E), carbapenem-resistant *Enterobacterales* (CRE), and *Pseudomonas aeruginosa* with difficult-to-treat resistance (DTR-P. *aeruginosa*). *Clinical Infectious Diseases*, 75(2): 187–212. <https://doi.org/10.1093/cid/ciac268>, Cited by: 661 citation the review
10. Meini S, Tascini C, Ceï O, Sozio E, Rossolini GM. AmpC β -lactamase-producing *Enterobacterales*: what a clinician should know. *Infection*, 2019; 47(3): 363–375.
11. Davido B, Bateman R, Dinh A, Lawrence C. Antimicrobial stewardship and the management of *Enterobacter cloacae* complex infections: Avoiding the third-generation cephalosporin trap. *J Hosp Infect*, 2020; 106(2): 312–320.
12. Kollef MH, Torres A, Shorr AF, Martin-Loeches I, Micek ST. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in prevention and treatment. *Crit Care*, 2021; 25(1): 180.
13. Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by ESICM). *Clin Microbiol Infect*, 2022; 28(4): 521–547.
14. Falconer SB, Lao UV, Moody J, et al. Characterization of AmpR-mediated regulation of chromosomal AmpC expression in *Enterobacter cloacae*. *Antimicrob Agents Chemother*, 2021; 65(5): e02210–20.
15. Patiño-Navarrte R, Rosas-Magaña G, Castro-Jaimes S, et al. Genomic and phenotypic characterization of *Enterobacter bugandensis* isolates associated with severe neonatal sepsis. *Emerg Microbes Infect*, 2023; 12(1): 2189402.
16. Bonomo RA. β -Lactamases: A real threat to ampicillin, amoxicillin, and cephalosporins. *Cold Spring Harb Perspect Med.*, 2017; 7(3): a0252
17. World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Geneva: World Health Organization, 2024.
18. Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L. Cefepime testing and clinical outcomes in infections caused by AmpC-producing *Enterobacterales*: A systematic review and meta-analysis. *Antimicrob Agents Chemother*, 2020; 64(11): e01230–20.
19. Centers for Disease Control and Prevention. Core Infection Prevention and Control Practices for Safe Healthcare Delivery in All Settings. Atlanta, GA: US Department of Health and Human Services, CDC, 2022.

20. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Optimizing β -lactam pharmacodynamics in the era of multidrug resistance: Extended and continuous infusions. Clin Pharmacokinet, 2021; 60(8): 981–995.
21. Sader HS, Castanheira M, Mendes RE, Flamm RK. Frequency and antimicrobial susceptibility of *Klebsiella aerogenes* and *Enterobacter cloacae* complex isolates from SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis., 2020; 96(3): 114945.
22. Falconer R, Sfeir MM, Bonomo RA. Synergistic combinations of aztreonam and ceftazidime-avibactam against NDM-producing Gram-negative pathogens: A mechanistic review. Lancet Infect Dis., 2024; 24(2): e115–e126.